RxDoctor Payments Data

Stephanie Welker, NP

Nurse Practitioner · Huntington, WVNPI 1851892525

Payments from drug & device makers

$1,964in general payments, 2019–2025

Across 91 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Indivior Inc.$330
  • Braeburn Inc.$248
  • Alkermes, Inc.$179
  • Merz North America, Inc.$129
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68

What the payments were for

  • Food & beverage$1,93498%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,964 in reported general payments places this provider in the 85th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$22,321
Medicare patients
50
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl126$40,985
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl430$34,505
Buprenorphine12$2,990
Ibuprofen52$430
Gabapentin28$202
Testosterone Cypionate12$163
Ondansetron Hcl14$147
Pregabalin15$128
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid22$104
Bupropion XlBupropion Hcl12$98
Clonidine Hcl18$51
Mirtazapine13$46
Cyclobenzaprine Hcl12$29
Amlodipine Besylate12$10
Omeprazole17$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$330$40,985126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →